Form 4: Cytek Biosciences Director Michael Holder Reports Stock Transactions

Director Michael Holder of Cytek Biosciences reports the acquisition and disposal of common stock and derivative securities.

Summary

• On May 19, 2025, Michael Holder, a director of Cytek Biosciences, engaged in transactions involving the company's stock.
• Holder acquired 1,454 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, Holder disposed of 1,454 shares of common stock.
• Following these transactions, Holder directly owns 7,997 shares of Cytek Biosciences common stock and 18,181 derivative securities in the form of Restricted Stock Units.
• The RSUs vest in installments on various dates, including August 18, November 18, March 10, and May 18.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is a standard practice for directors and officers of publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company director.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Michael Holder, Stock Transaction, Restricted Stock Units, Director, Beneficial Ownership